A team of 10 U.S.-based investigators delved deeper into how autosomal dominant polycystic kidney disease affects patients’ health-related quality of life and pain levels. Here’s what they found.

Experts recently developed 23 consensus practice points/statements regarding the use of nephrectomy in autosomal dominant polycystic kidney disease (ADPKD). Regardless of when it was performed in ...

Please provide your email address to receive an email when new articles are posted on . Of the included patients, 2.5% were on dialysis and 23% had a kidney transplant. Autosomal dominant PKD affects ...

(RTTNews) - Thursday, Vertex Pharmaceuticals Inc. (VRTX) announced that the FDA has cleared the Investigational New Drug Application or IND for VX-407 for the treatment of autosomal dominant ...

Please provide your email address to receive an email when new articles are posted on . The eGFR decline rate for patients on tolvaptan was –2.58 mL/min/1.73 m² per year. For patients in the control ...

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2025 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and ...

TUCSON, Ariz., Sept. 19, 2024 — Critical Path Institute (C-Path) is thrilled to announce its Polycystic Kidney Disease Outcomes Consortium (PKDOC) has been awarded an Autosomal Dominant ...

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease and the fourth leading cause of end-stage kidney disease in adults worldwide. 1,2 It results in the ...

SAN FRANCISCO, Nov. 5, 2025 /PRNewswire/ -- Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D.